A total of 23 billionaire-led funds held stakes in Viatris (NASDAQ: VTRS) at the end of the second quarter, while 22 funds held stakes in BioCryst (NASDAQ: BCRX). Viatris's Q2 revenue rose about 4.9% year over year, and management raised its fiscal 2026 guidance across all key metrics. The FDA also approved Gwyn Lo, a once-weekly contraceptive patch from Viatris, which the company plans to launch later in fiscal 2026.